Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.
GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.
ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs.
Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic company established in 2019 and headquartered in Suzhou, China, with a research and development office in Singapore. The company specializes in developing advanced diagnostic technologies aimed at infectious diseases, cancer, and chronic diseases. Its offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Through these technologies, Virtue Diagnostics aims to enhance disease detection and management, contributing to improved healthcare outcomes.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Abogen Biosciences
Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Ieso Digital Health Ltd. specializes in providing online evidence-based cognitive behavioral therapy (CBT) to individuals facing various mental health challenges, including anxiety and depression. The company's unique online service facilitates real-time communication between accredited therapists and patients through a secure virtual environment, where sessions are conducted via text. This approach not only mirrors traditional face-to-face interactions but also offers greater convenience for users. Ieso began its operations in the UK in 2000 and has since expanded into the US market, collaborating with Medicaid and commercial health plans to enhance access to mental health services. The company’s therapy model has demonstrated effectiveness, requiring fewer sessions to achieve recovery and showing improved outcomes compared to conventional therapy methods. Ieso serves a diverse clientele, including health providers, private individuals, and businesses, and is recognized for its rapid growth in the digital health sector.
Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.
DeepCure Inc. offers drugs discovery services using artificial intelligence technology. Its products include De-novo Lead Discovery, Artificial Intelligence-driven Lead Optimization, and MoIDB. De-novo Lead Discovery uses artificial intelligence algorithms to analyze drug candidates from virtual library. Artificial Intelligence-driven Lead Optimization identifies optimization steps to improve the development of drugs. MolDB is designed to maximize scale, diversity, and synthesizability of chemical search space. DeepCure Inc. develops new drug through molecular feature extraction, MoIDB, artificial intelligence predictive modeling and feedback loop. The company was founded in 2018 and is based in Boston, Massachusetts.
Signet Therapeutics
Seed Round in 2021
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.
Etern is developing small molecule innovative drugs for oncology therapies.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, utilizing sensors, music, and artificial intelligence to enhance therapeutic outcomes. Founded in 2015 and headquartered in Portland, Maine, the company focuses on patients affected by conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. MedRhythms develops evidence-based interventions aimed at improving walking, speech, cognitive abilities, and overall functional outcomes through the intersection of music and neuroscience. By employing innovative technology and direct brain stimulation techniques, the company aims to provide effective rehabilitation solutions that leverage the therapeutic benefits of music for neurological recovery.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.
Triastek Co. Ltd., founded in 2015 and based in Nanjing, China, specializes in the manufacture of 3D printed pharmaceuticals and related medical equipment. The company offers a range of products, including blockbuster and orphan drugs, as well as complex drug delivery technologies. Triastek develops proprietary 3D printing technology that encompasses the entire process from drug formulation design to continuous production. Its Melt Extrusion Deposition (MED) technology is applicable to solid formulations, enabling innovative drug delivery and development solutions. The company has also filed patent applications for its technologies, emphasizing its commitment to advancing pharmaceutical manufacturing through 3D printing.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.
Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, the company aims to address the significant morbidity and mortality associated with sleep apnea, which affects over 20 million Americans. Apnimed's approach targets the neurobiological mechanisms that lead to airway obstruction, offering a simple, orally dosed treatment option. This strategy contrasts with current therapies, which primarily rely on positive pressure devices like CPAP, as well as other less commonly used methods such as mandibular advancement devices and surgical interventions. Apnimed's therapeutics are designed to alleviate both the physiological and symptomatic effects of obstructive sleep apnea, providing a safe and effective solution that addresses the underlying biology of the condition.
PhoreMost Limited, a drug discovery company, engages in identifying new druggable targets for cancer and other unmet diseases. It develops Site-Seeker, a platform that systematically unmasks druggable sites in the human genome and links them to useful therapeutic functions in a live-cell context. The company was incorporated in 2014 and is based in Cambridge, United Kingdom.
Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company has a portfolio of breakthrough technologies aimed at addressing various eye care challenges, including rare diseases through gene therapy. Established by prominent life sciences investors, Arctic Vision is led by a team of experienced professionals from the ophthalmic industry, bringing extensive expertise in research, development, and commercialization of eye care products. The company aims to deliver effective solutions not only in China but also across Asia and globally.
Zhishan Weixin Biotechnology
Series A in 2021
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.
neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.
New Amsterdam Pharma B.V. is a clinical-stage biopharmaceutical company based in Naarden, the Netherlands, focused on researching and developing innovative therapies for cardio-metabolic diseases. Founded in 2019, the company is dedicated to improving patient care for those with metabolic disorders, particularly where existing treatments are inadequate or poorly tolerated. Its lead product, obicetrapib, is a next-generation oral CETP inhibitor designed to provide a preferred LDL cholesterol-lowering option for patients who experience statin intolerance or for those with Arteriosclerotic Cardiovascular Disease and Familial Hypercholesterolemia who are on maximally tolerated statin therapy.
Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.
AliveX is a developer of an AI-driven immunology platform that focuses on biomarker discovery for early cancer screening, precision medicine, and treatment monitoring. By integrating multi-omics data, artificial intelligence, and computational biology, the platform aims to decode the human immune system. This innovative approach enables collaboration with leading clinicians, research institutions, and pharmaceutical companies to address significant clinical challenges. AliveX's efforts are directed towards transforming life sciences research and advancing the next generation of precision diagnostics and treatments in the field of immunology.
Tallac Therapeutics, Inc. develops immunotherapies for cancer patients. Tallac Therapeutics, Inc. was formerly known as Tollnine, Inc. The company was founded in 2018 and is based in Burlingame, California.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.
Beijing Naxions Technology Co., Ltd. is a healthcare-focused company that specializes in providing digital marketing services tailored for the pharmaceutical industry. Founded in 2014 and headquartered in Chaoyang District, China, with additional offices in Shanghai, Naxions has developed a software-as-a-service (SaaS) platform designed to enhance pharmaceutical sales management. The platform offers a range of services, including data capture, cleaning, and analysis, alongside features for content sharing and project management. By leveraging internet technology, Naxions aims to support pharmaceutical enterprises in developing their brand image and increasing market awareness through real-time data analysis and visualization.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Revolo Biotherapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and immunological diseases, such as asthma, atopic dermatitis, and inflammatory bowel disease. The company's approach is grounded in the natural mechanisms employed by Mycobacterium tuberculosis to evade the host immune system, allowing it to suppress inflammatory responses. Unlike existing treatments that aim to suppress the immune system and often require chronic dosing with significant side effects, Revolo's immune-resetting therapies have shown promise in preclinical and human studies by safely transitioning the immune system from a pro-inflammatory state to a regulatory one. This novel strategy aims to induce long-term disease remission without the adverse effects typically associated with conventional therapies. Founded in 2001 and based in London, Revolo Biotherapeutics is dedicated to transforming the treatment landscape for patients suffering from allergic and immune-mediated conditions.
Prescryptive Health, Inc. is a digital health company based in Redmond, Washington, that operates a prescription benefits platform aimed at enhancing accessibility, affordability, and personalization in the medication market. Established in 2017, the company provides a range of services, including the analysis of existing plan designs, recommendations for new plans, and assistance with member enrollment. Its platform offers users, including employers, health plans, providers, pharmacies, and pharmaceutical companies, direct access to unbiased market pricing and essential information about prescribed treatments. This enables patients to understand their out-of-pocket expenses, insurance coverage, and available lower-cost alternatives at the point of care, thereby promoting informed decision-making in the prescription drug market.
Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Vesigen, Inc. is a biotechnology company focused on developing innovative therapeutic products that utilize extracellular vesicle delivery technology to target intracellular sites. Founded in 2020 and based in Cambridge, Massachusetts, the company employs its proprietary ARMMs technology to facilitate the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This approach aims to overcome the challenges associated with intracellular drug delivery, thereby broadening the range of potential druggable targets and enabling the creation of novel treatments for various diseases. Vesigen's mission is to address unmet medical needs through its advanced therapeutic solutions.
Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company has a portfolio of breakthrough technologies aimed at addressing various eye care challenges, including rare diseases through gene therapy. Established by prominent life sciences investors, Arctic Vision is led by a team of experienced professionals from the ophthalmic industry, bringing extensive expertise in research, development, and commercialization of eye care products. The company aims to deliver effective solutions not only in China but also across Asia and globally.
neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses.
Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Adjuvance Technologies, Inc. is a biopharmaceutical company based in Lincoln, Nebraska, founded in 2009. The company specializes in the design and manufacture of adjuvant molecule vaccines, which enhance the immune response in vaccination. Its product offerings include Saponex, a synthetic version of the naturally occurring adjuvant QS-21; TQL1055, a synthesized novel analogue; and Triterpene Saponin Synthesis Technology (TriSST), which focuses on the synthesis of novel compositions. Additionally, Adjuvance provides TiterQuil, a collection of unique molecules that do not occur in nature. Through its innovative approach, Adjuvance Technologies aims to advance vaccine efficacy and contribute to public health.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.
IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.
ZielBio, Inc. is a biotechnology company focused on identifying high-value disease targets and developing therapeutic interventions to enhance patient outcomes. The company is based in Charlottesville, Virginia, and utilizes its proprietary drug discovery platform, Zielfind, which integrates functional high-throughput screening with large content data analytics to pinpoint valuable targets. ZielBio's lead compound, ZB131, is a humanized monoclonal antibody designed to target cell surface plectin, a significant player in various cancers including ovarian, pancreatic, lung, and colorectal cancer. Founded in 2010, ZielBio aims to transform disease treatment through innovative therapeutic approaches.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients with autoimmune diseases and cancers. Established in 2009, the company is known for its lead product, annexuzlimab, a monoclonal antibody designed to address various autoimmune conditions. MedAnnex aims to create first-in-class antibody therapies that significantly enhance the quality of life for individuals affected by these serious health issues. Through its research and development efforts, the company is committed to advancing therapeutic options in the biotechnology sector.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Allysta Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic peptides for eye diseases. The company’s products include ALY688 for treatment of inflammatory ocular surface disorders. It develops medicines for dry eye disease and liver disease. Allysta Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Belmont, California.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
Apic Bio, Inc. is a biotechnology company focused on developing gene therapies for rare and complex neurological and liver diseases. Founded in 2017 and based in Cambridge, Massachusetts, the company specializes in treating conditions such as alpha-1 antitrypsin deficiency. Apic Bio utilizes a gene therapy platform that employs a Dual Function Vector (df-AAV) to simultaneously silence the Z-AAT protein and enhance the M-AAT protein in the liver. This innovative approach aims to address the challenges of genetic diseases through targeted therapies, providing hope for patients with undertreated conditions.
Retrotope Inc. is a biotechnology company that focuses on developing drugs for the treatment of degenerative and intractable diseases, particularly neurological disorders. Based in Los Altos, California, the company aims to preserve and restore mitochondrial health through a novel drug platform that targets metabolic processes linked to oxidative stress. Retrotope's portfolio includes RT001, a drug designed for infantile neuroaxonal dystrophy, and it actively works on treatments for conditions such as Parkinson's disease, Alzheimer's disease, mitochondrial myopathies, and retinopathies. Established in 2006, Retrotope employs innovative approaches, including the isotope effect, to slow damaging biological pathways, thereby addressing various major classes of biopolymers and advancing its commitment to improving patient outcomes in degenerative diseases.
Xgene Pharmaceutical Inc. is a pharmaceutical company founded in 2015 and based in the Cayman Islands. The company specializes in the development of small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Through its research and development efforts, Xgene Pharmaceutical seeks to address significant medical needs in these areas.
Triastek Co. Ltd., founded in 2015 and based in Nanjing, China, specializes in the manufacture of 3D printed pharmaceuticals and related medical equipment. The company offers a range of products, including blockbuster and orphan drugs, as well as complex drug delivery technologies. Triastek develops proprietary 3D printing technology that encompasses the entire process from drug formulation design to continuous production. Its Melt Extrusion Deposition (MED) technology is applicable to solid formulations, enabling innovative drug delivery and development solutions. The company has also filed patent applications for its technologies, emphasizing its commitment to advancing pharmaceutical manufacturing through 3D printing.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
The Nue Co. Ltd. specializes in the production of science-backed nutritional supplements derived from organic ingredients. Founded in 2016 and based in London, the company emphasizes simplicity and creativity, inspired by Danish principles. Its product range includes vitamins, milk protein, plant protein, magnesium, prebiotics, and probiotics, all formulated without toxic preservatives, additives, or fillers. The ingredients are responsibly sourced and clinically proven to address various health concerns, including fatigue, skin issues, inflammation, and digestive problems. The Nue Co. operates on a subscription model through its online platform, ensuring that consumers have easy access to high-quality supplements. Committed to sustainability, the company limits plastic packaging and aims to reduce its carbon footprint, while maintaining transparency and high standards in ingredient sourcing.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.
Xiaolu Clinic is an online platform connecting traditional Chinese medicine providers with consumers. It offers online traditional Chinese medicine consultancy services for patients with chronic disease and those suffering from sub-optimal health, areas that traditional Chinese medicine might treat with herbal mixtures and dietary augmentation. Users can be evaluated by traditional Chinese medicine doctors and purchase herbal remedies online, as well as engage in treatment monitoring and post-treatment analysis. It also provides health management services for staff at big companies, including Baidu Inc., China Life Insurance (Group) Co., and Tencent Holdings Ltd. The Beijing-based company was founded in 2016.
Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.
Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
Luqa Pharmaceuticals Co., Ltd. is a specialty pharmaceutical company focused on the Chinese market, primarily engaged in the acquisition, development, and commercialization of healthcare products. The company offers a diverse portfolio that includes dermatological and oral care products. Its dermatological offerings feature Ebernet, an eberconazole cream for fungal skin infections, and Strataderm, a silicone gel for scar treatment and prevention. In the oral care segment, Luqa provides Lacteol, a probiotic for infants and immunocompromised patients, and GelX, a medical device for managing oral cavity pain from conditions like mucositis and stomatitis. Other products include GelX Xero for dry mouth relief, Aftacure for oral mucosal lesions, Ialuxid Gel for post-surgical wounds, and Podofilm for benign epithelial formations. Established in 2010 and based in Central, Hong Kong, Luqa Pharmaceuticals is dedicated to enhancing patient quality of life through innovative healthcare solutions.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
Vigeo Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutic agents for treating advanced malignant tumors. Established in 2011, the company is working on a first-in-class drug discovery pipeline aimed at reprogramming the tumor immune microenvironment (TIME). Its lead anti-cancer agent is a peptide fragment derived from the prosaposin protein, which inhibits metastasis and tumor growth by promoting the production of an inhibitory molecule within the tumor microenvironment. Vigeo Therapeutics plans to initiate multiple combination studies to assess the efficacy of its lead product, VT1021, in conjunction with various chemotherapies and anti-PD-1 antibodies, with the goal of improving treatment options for patients with multiple types of cancer.
Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.
Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.
Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
DNAtrix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in virus-driven immunotherapies for cancer treatment. The company develops modified viruses designed to selectively target and kill cancer cells, with its lead product, DNX-2401, focused on glioblastoma, an aggressive and currently incurable brain tumor. This oncolytic immunotherapy has shown promising early results, having been administered to over 35 patients. In addition to DNX-2401, DNAtrix is advancing other therapies, including DNX-2440 and DNX-2450 for solid tumors, and MYX-135 for hematological malignancies. The company aims to expand its platform technology to address a broader range of cancers, including brain metastases, ovarian, and pancreatic cancer. DNAtrix has formed a strategic partnership with Valo Therapeutics to enhance its research and development efforts.
Synchroneuron Inc. is a biopharmaceutical company focused on developing therapies for tardive dyskinesia and other neuropsychiatric disorders. Its lead candidate, SNC-102, is a sustained-release formulation of acamprosate calcium that aims to enhance pharmacokinetic properties compared to existing formulations. SNC-102 is designed to address tardive dyskinesia by modulating both excitatory and inhibitory neurotransmission in the neural circuits responsible for involuntary movements. The drug is currently undergoing evaluation in phase 2 trials for tardive dyskinesia and Tourette syndrome, as well as in phase 1 trials for combat-related posttraumatic stress disorder. Founded in 2011 and based in Duxbury, Massachusetts, Synchroneuron was previously known as Eukinetix, Inc.
Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.
Senhwa Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2012 and headquartered in New Taipei City, Taiwan, the company is advancing several drug candidates through clinical trials. Notably, CX-4945 is undergoing phase I/II trials for cholangiocarcinoma in combination with gemcitabine and cisplatin, while CX-5461 is being tested in phase I studies for advanced hematologic malignancies and solid tumors, including breast cancer. Additionally, CX-4945 is involved in trials for advanced basal cell carcinoma and recurrent SHH medulloblastoma through pediatric brain tumor consortium studies. Senhwa Biosciences aims to identify and develop therapies that have the potential to significantly enhance treatment outcomes for patients, focusing on underexploited targets that could improve the standard of care.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
Envisia Therapeutics Inc. is a biotechnology company dedicated to discovering and developing innovative therapies for ocular conditions. Founded in 2013 and based in Durham, North Carolina, the company addresses significant unmet medical needs in ophthalmology, particularly for conditions like glaucoma. Envisia's lead product, ENV515, is a prostaglandin analogue formulated with a biodegradable PRINT particle technology, designed to provide sustained intraocular pressure reduction over several months. The company's research and development efforts focus on overcoming barriers associated with traditional ocular therapies, such as poor drug uptake and systemic side effects, by utilizing biocompatible polymers and extended-release delivery systems. With an increasing demand for effective ocular therapeutics due to a rapidly aging population, Envisia aims to significantly improve patient outcomes and adherence to treatment protocols in the field of eye care.
Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.
ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Synchroneuron Inc. is a biopharmaceutical company focused on developing therapies for tardive dyskinesia and other neuropsychiatric disorders. Its lead candidate, SNC-102, is a sustained-release formulation of acamprosate calcium that aims to enhance pharmacokinetic properties compared to existing formulations. SNC-102 is designed to address tardive dyskinesia by modulating both excitatory and inhibitory neurotransmission in the neural circuits responsible for involuntary movements. The drug is currently undergoing evaluation in phase 2 trials for tardive dyskinesia and Tourette syndrome, as well as in phase 1 trials for combat-related posttraumatic stress disorder. Founded in 2011 and based in Duxbury, Massachusetts, Synchroneuron was previously known as Eukinetix, Inc.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.